ライフサイエンスコーパス: rhinitis

1 0.74,0.86], P < .001; current wheeze, AD and rhinitis).

2 al secretion (r = 0.69, P = .06) in allergic rhinitis.

3 sient rhinitis, and 6.6% (n = 51) persistent rhinitis.

4 y associated with the presence of asthma and rhinitis.

5 mmon childhood conditions such as asthma and rhinitis.

6 with (n = 19) or without (n = 28) asthma and rhinitis.

7 rgic disorders including asthma and allergic rhinitis.

8 verlap with other diseases, such as allergic rhinitis.

9 ion profiles were associated with asthma and rhinitis.

10 of sensitization associated with asthma and rhinitis.

11 ported diagnosis of food allergy or allergic rhinitis.

12 p to 25% of cases of occupational asthma and rhinitis.

13 nduce type 2 cytokines production in baker's rhinitis.

14 between subjects with and without asthma and rhinitis.

15 isk factor for the development of asthma and rhinitis.

16 tion was found mainly in those with allergic rhinitis.

17 ociations for LCADs with comorbid wheeze and rhinitis.

18 sitized giving a high prevalence of allergic rhinitis.

19 was only positively associated with allergic rhinitis.

20 1.28; 95% CI 1.04-1.58) were associated with rhinitis.

21 l immunotherapy in the treatment of allergic rhinitis.

22 subcutaneous and sublingual immunotherapy in rhinitis.

23 children and adults with asthma and allergic rhinitis.

24 lects the real-life epidemiology of allergic rhinitis.

25 vident for allergic phenotypes of asthma and rhinitis.

26 t, and more severe and commonly intermittent rhinitis.

27 CI CSMS score and the MASK control score for rhinitis.

28 ive, safe treatment for HDM-induced allergic rhinitis.

29 ssessment in patients with seasonal allergic rhinitis.

30 with moderate to severe HDM-induced allergic rhinitis.

31 characteristic features of seasonal allergic rhinitis.

32 rm exposure to air pollution and severity of rhinitis.

33 not recommended in the routine evaluation of rhinitis.

34 ithelial cells in type 2 asthma and allergic rhinitis.

35 opic dermatitis/eczema, asthma, and allergic rhinitis?

36 ] 1.89, 95% CI 1.26-2.84; p=0.004), allergic rhinitis (3.06, 2.26-4.15; p<0.0001), childhood pneumoni

37 had significantly longer median durations of rhinitis (8 vs 6 days; P = .0008), cough (8 vs 6 days; P

38 d: 7.6% (n = 59) were termed early transient rhinitis, 8.6% (n = 66) late transient rhinitis, and 6.6

39 demonstrate that the closely related equine rhinitis A virus (ERAV) L(pro) also cleaves G3BP1 and G3

40 Seasonal allergens were associated with rhinitis, a longer time to asthma development, and more

41 In allergic rhinitis, a relevant outcome providing information on th

42 fic areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, d

43 No subject had a history of asthma/allergic rhinitis: all had negative results for aeroallergen skin

44 eases, including food allergy (FA), allergic rhinitis, allergic asthma, and allergic rhinoconjunctivi

45 me estimated weighted prevalence of reported rhinitis, allergic conjunctivitis and eczema was 43.3%,

46 f allergy-related diseases (ARDs), including rhinitis, allergic conjunctivitis and eczema, is on the

47 c conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esop

48 reduction in the risk of ever asthma, AD and rhinitis amongst rural children with individual supply:

49 1), COPD (n = 15), Asthma and COPD (n = 15), Rhinitis and Asthma (n = 5), and Rhinosinusitis (n = 6).

50 ute to the onset and aggravation of allergic rhinitis and asthma among other chronic respiratory dise

51 Rhinitis and asthma are linked, but substantial knowledg

52 n immunotherapy (AIT) treatment for allergic rhinitis and asthma is used by 2.6 million Americans ann

53 dy offers strong support to the concept that rhinitis and asthma represent the manifestations of 1 di

54 re nowadays the third cause of allergy after rhinitis and asthma with a significant increase in preva

55 r 1 year with algorithm-based treatments for rhinitis and asthma.

56 ontrol, and investigate associations between rhinitis and asthma.

57 lead to IgE sensitization and development of rhinitis and asthma.

58 flect the real-life epidemiology of allergic rhinitis and asthma.

59 tive in patients with IgE-dependent allergic rhinitis and asthma.

60 ation of any human milk feeding and allergic rhinitis and atopic dermatitis in childhood.

61 Information on medical diagnosis of asthma, rhinitis and atopic dermatitis was retrieved for each pa

62 associated with increased risks of allergic rhinitis and eczema up to 18 years, and sensitization an

63 efractory disorders such as asthma, allergic rhinitis and food allergy, mainly by inducing T helper (

64 -IS Question 9) are similar in users without rhinitis and in those with mild rhinitis (scores 0-2).

65 The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative clas

66 gies in rhinitis control, the ARIA (Allergic Rhinitis and its Impact on Asthma) score ranging from 0

67 We sought to determine the prevalence of rhinitis and its phenotypes in children and adolescents

68 Allergic rhinitis and LAR share many clinical features including

69 he effect is mainly confined to non-allergic rhinitis and more pronounced in adolescents than in youn

70 ve study, we enrolled patients with allergic rhinitis and sensitization to house dust mites.

71 allergy-related outcomes (wheeze, urticaria, rhinitis and visible flexural dermatitis), and effect mo

72 tral Europe and is a major cause of allergic rhinitis and, possibly, asthma symptoms.

73 t of house dust mites (HDM)-induced allergic rhinitis and/or asthma based on recent real-life data.

74 mite allergoid in the treatment of allergic rhinitis and/or asthma.

75 Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment

76 lergic disease (asthma, eczema, and allergic rhinitis) and corticosteroid use.

77 sient rhinitis, 8.6% (n = 66) late transient rhinitis, and 6.6% (n = 51) persistent rhinitis.

78 ted with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years

79 es were offspring's current asthma, allergic rhinitis, and allergen sensitization at a median age of

80 confounders on the prevalence of asthma and rhinitis, and allergic multimorbidity in each cohort sep

81 HDM were associated with more common rhinitis, and Alternaria was associated with asthma.

82 MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of mult

83 no effect on atopic sensitization, allergic rhinitis, and asthma at 6 years.

84 Down syndrome, astigmatism, myopia, allergic rhinitis, and asthma were positively associated with KC

85 eases, including atopic dermatitis, allergic rhinitis, and asthma.

86 Evidence on food allergies, allergic rhinitis, and atopic dermatitis is limited.

87 gic disorders include food allergy, allergic rhinitis, and certain forms of asthma resulting from the

88 nto the shared or unique etiology of asthma, rhinitis, and eczema.

89 allergic symptoms and shared between asthma, rhinitis, and eczema.

90 rns were investigated in relation to asthma, rhinitis, and eczema.

91 ns associate with the development of asthma, rhinitis, and eczema.

92 ared molecular mechanisms underlying asthma, rhinitis, and eczema.

93 ers such as asthma, allergic and nonallergic rhinitis, and food allergy.

94 values, whereas chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease were only

95 dinal associations between prevalent asthma, rhinitis, and IgE sensitization and mold or dampness ind

96 es, including food allergy, asthma, allergic rhinitis, and mental health disorders.

97 ma aOR = 2.61 [95% CI = 2.14-3.18]; allergic rhinitis aOR = 1.96 [95% CI = 1.58-2.42]; eosinophil cou

98 l barrier is found in patients with allergic rhinitis (AR) and asthma; however, the underlying mechan

99 a useful tool for the diagnosis of allergic rhinitis (AR) and local allergic rhinitis (LAR) and migh

100 Allergic rhinitis (AR) and local allergic rhinitis (LAR) are defi

101 omprehensive practice parameter for allergic rhinitis (AR) and nonallergic rhinitis (NAR) provides up

102 symptoms (OAS) (4.46 [4.19-4.75]), allergic rhinitis (AR) comorbidity (2.82 [2.68-2.95]), asthma com

103 nto optimizing treatment to improve allergic rhinitis (AR) control.

104 apy (AIT) in seasonal and perennial allergic rhinitis (AR) depends on the definition of pollen exposu

105 Allergic rhinitis (AR) is caused by immunoglobulin E (IgE)-mediat

106 whereas evidence for remodelling in allergic rhinitis (AR) is conflicting.

107 Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or wor

108 received at least three symptomatic allergic rhinitis (AR) prescriptions in successive mite seasons.

109 Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthma were ba

110 challenge (NAC) is a human model of allergic rhinitis (AR) that delivers standardized allergens local

111 y (AIT) prevents the progression of allergic rhinitis (AR) to asthma.

112 Allergic rhinitis (AR) was defined as one or more positive result

113 disease-modifying intervention for allergic rhinitis (AR) with long-term efficacy.

114 Allergic rhinitis (AR), allergic conjunctivitis (AC), and allergi

115 ovocation test (NAPT) into the LAR, allergic rhinitis (AR), and nonallergic rhinitis (NAR) phenotypes

116 of current atopic dermatitis (AD), allergic rhinitis (AR), asthma and sensitization against aeroalle

117 airment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL in nonall

118 ite the socioeconomic importance of allergic rhinitis (AR), very few prospective studies have been pe

119 bsequent risk for diseases, such as allergic rhinitis (AR).

120 food allergy [IgE-FA], asthma, and allergic rhinitis [AR]) was ascertained in a pediatric primary ca

121 Rates of allergic rhinitis, asthma and other food allergies in PwPA were 5

122 dermatitis (AD), food allergy (FA), allergic rhinitis, asthma, and atopic sensitization at 6 years af

123 n sensitization, atopic dermatitis, allergic rhinitis, asthma, and challenge-proved food allergy.

124 d in the pathophysiology of eczema, allergic rhinitis, asthma, and food allergy.

125 ally effective and safe in treating allergic rhinitis, asthma, and stinging insect allergy in Europe

126 m four recent systematic reviews on allergic rhinitis, asthma, food allergy and venom allergy, respec

127 alence of allergic diseases such as allergic rhinitis, asthma, food allergy, and atopic dermatitis ha

128 have KC, and patients with asthma, allergic rhinitis, astigmatism, myopia, or Down syndrome had high

129 Symptoms of wheeze or rhinitis at 7 y CA did not differ between high- and stan

130 lergic disease symptoms including wheeze and rhinitis at 7 y CA were the main outcomes.

131 lected from 40 adults with seasonal allergic rhinitis at baseline and at 4, 8, 16, 28, and 52 weeks.

132 ciated with a lower prevalence of asthma and rhinitis at the age of 7(0.41 [0.18:0.97] and 0.37 [0.15

133 versus breast with food allergies, allergic rhinitis, atopic dermatitis, and asthma.

134 -up revealed significant effects in allergic rhinitis by measuring the number of AR medications and d

135 Infective rhinitis can be caused by viruses, and less commonly by

136 the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19.

137 ation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma.

138 lop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma.

139 ponse develops in affected organs in asthma, rhinitis, chronic rhinosinusitis, eosinophilic esophagit

140 asthma-related comorbidities are discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflu

141 al Allergy in 2018; epidemiology, asthma and rhinitis, clinical allergy and allergens are all covered

142 ity of, and overlap in the risk factors for, rhinitis, conjunctivitis and eczema-similar to asthma ri

143 g/asthma; six, food allergy; three, allergic rhinitis/conjunctivitis.

144 nts in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of l

145 tom severity and medication requirements for rhinitis control, and investigate associations between r

146 echnology has been used to appraise allergic rhinitis control, but more data are needed.

147 ess the importance of mobile technologies in rhinitis control, the ARIA (Allergic Rhinitis and its Im

148 and, if needed in patients with uncontrolled rhinitis despite medications or with long-lasting sympto

149 Control of days with rhinitis differed between no (best control), single (goo

150 nths subcutaneous immunotherapy (SCIT) in 25 rhinitis, documenting changes in immunoinflammatory path

151 frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough.

152 Controls were defined as not having asthma, rhinitis, eczema, allergy, emphysema, or chronic bronchi

153 Asthma, allergic rhinitis, eosinophil count of at least 150 cells per mic

154 Clinical factors, including asthma, allergic rhinitis, eosinophil count of at least 150 cells per mic

155 d by a higher prevalence of asthma, allergic rhinitis, eosinophil count of at least 150 cells per mic

156 Most allergic diseases, such as asthma, rhinitis, food allergies, and atopic dermatitis, are gen

157 such as atopic dermatitis, asthma, allergic rhinitis, food allergy, contact allergy, and hand eczema

158 We propose the term dual allergic rhinitis for this rhinitis phenotype.

159 ent asthma, allergen sensitization, allergic rhinitis, fractional exhaled nitric oxide (FeNO) and lun

160 Participants with rhinitis from 2 multicenter European cohorts (Epidemiolo

161 ization in adolescence will develop allergic rhinitis in adult life.

162 n in adolescence, 53%-78% developed allergic rhinitis in adulthood.

163 ed as a choice for the treatment of allergic rhinitis in childhood.

164 SCIT was effective for allergic rhinitis in childhood.

165 equent climate change on asthma and allergic rhinitis in children and adults and addresses the policy

166 for grass and birch pollen-induced allergic rhinitis in other European geographical areas such as Au

167 We investigated SCIT for allergic rhinitis in our hospital for the past 17 years.

168 : For initial treatment of seasonal allergic rhinitis in persons aged 12 years or older, routinely pr

169 ment of moderate to severe seasonal allergic rhinitis in persons aged 12 years or older, the clinicia

170 sment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult popu

171 Risk factors associated with reported rhinitis in the last 12 months were city residence at bi

172 Allergic diseases (eczema, wheeze and rhinitis) in children often present as heterogeneous phe

173 lence of allergic sensitisation and allergic rhinitis increased in a general adult Danish population

174 %) to adulthood (57%); particularly allergic rhinitis increased with an incidence rate of 17.5/1000 p

175 Allergic rhinitis induced by house dust mites (HDMs) is a highly

176 nusitis, pharyngitis, otitis media, allergic rhinitis, influenza, pneumonia, and unspecified upper re

177 Risk factors for early transient rhinitis involve a combination of genetic and early envi

178 saicin treatment in patients with idiopathic rhinitis (IR) is based on ablation of the transient rece

179 Baker's rhinitis is a kind of occupational allergic rhinitis mai

180 While treatment for atopic rhinitis is aimed mostly to relieve symptoms, only aller

181 Rhinitis is almost ubiquitous in urban children with ast

182 Treatment of rhinitis is associated with benefits for asthma.

183 Allergic rhinitis is diagnosed by history and examination, suppor

184 The natural history of childhood rhinitis is not well described.

185 In contrast, persistent rhinitis is strongly associated with atopic risk and lik

186 Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system.

187 food allergy, allergic asthma, and allergic rhinitis, it is logical that restoring the skin barrier

188 rial for Japanese children with HDM allergic rhinitis (JapicCTI-152953).

189 Two additional serious AEs were reported (rhinitis [JNJ-8678]; pneumonia [placebo]).

190 of allergic rhinitis (AR) and local allergic rhinitis (LAR) and might serve to design and monitor all

191 Allergic rhinitis (AR) and local allergic rhinitis (LAR) are defined by nasal reactivity to aeroal

192 about the natural history of local allergic rhinitis (LAR) is limited.

193 Over 30% of local allergic rhinitis (LAR) patients self-report bronchial symptoms s

194 initis (SAR), eight perennial local allergic rhinitis (LAR), six nonallergic rhinitis (NAR), and six

195 ase phenotype has been termed local allergic rhinitis (LAR).

196 rhinitis is a kind of occupational allergic rhinitis mainly caused by intranasal exposure to wheat a

197 ironmental exposures, whereas late transient rhinitis may relate to maternal factors and early respir

198 A total of 1408 adults with rhinitis (mean age, 52 years; 46% men, 81% from the Euro

199 ded diabetes mellitus (DM), asthma, allergic rhinitis, mitral valve prolapse, collagen vascular disea

200 MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic r

201 "Mixed rhinitis" (MR) patients have more than one major etiolog

202 ithout allergy (n = 12), those with allergic rhinitis (n = 12), or those with allergic rhinitis with

203 ng that in a comparator cohort with allergic rhinitis (n = 149).

204 atients suffering from IgE-mediated allergic rhinitis (n=10) and healthy controls (n=10).

205 Participants with allergic rhinitis (n=42) were randomized to receive eight weekly

206 LAR, allergic rhinitis (AR), and nonallergic rhinitis (NAR) phenotypes.

207 r for allergic rhinitis (AR) and nonallergic rhinitis (NAR) provides updated guidance on diagnosis, a

208 e degree of impairment in QoL in nonallergic rhinitis (NAR) remained unknown for a long time, due to

209 cal allergic rhinitis (LAR), six nonallergic rhinitis (NAR), and six healthy control (HC) individuals

210 Female gender, allergic rhinitis, obesity, and family history of asthma remained

211 tis," "Transient wheeze," "Eczema only" and "Rhinitis only" were used as the study outcome.

212 Participants with allergic rhinitis or allergic rhinitis with asthma had increased

213 creased in patients with asthma and allergic rhinitis or in acutely exuding healthy airways.

214 ergic asthma (OR 1.80; 95% CI 1.27-2.55) and rhinitis (OR 1.41; 95% CI 1.03-1.93).

215 een OA caused by HMW agents and work-related rhinitis (OR [95% CI]: 4.79 [3.28-7.12]), conjunctivitis

216 a (OR, 1.56; 95% CI, 1.18-2.05) and allergic rhinitis (OR, 1.68; 95% CI, 1.34-2.11) had a smaller eff

217 .52] and 4.56 [95% CI, 2.35-8.52]), allergic rhinitis (OR, 22.4 [95% CI, 11.67-44.54] and 13.97 [95%

218 lative with parent-reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor).

219 the increased occurrence of asthma, allergic rhinitis, or both after atopic dermatitis (AD) onset.

220 ms from at least 1 allergic disease (asthma, rhinitis, or eczema) and positive serum-specific IgE to

221 during infancy increases the risk of asthma, rhinitis, or IgE sensitization in children followed from

222 nger (p < .001), with a higher prevalence of rhinitis (p < .001) and previous food allergy (p < .001)

223 Perennial allergic rhinitis (PAR) represents a global and public health pro

224 In PBMCs of allergic rhinitis participants, 42 sites showed significant DNA m

225 of donors (32 healthy controls, 43 allergic rhinitis patients and 192 asthmatics with different phen

226 as nasal secretions of AR but not idiopathic rhinitis patients rapidly decreased epithelial barrier i

227 A significant proportion of rhinitis patients without systemic IgE-sensitisation tes

228 -2-month interval in AR, LAR and nonallergic rhinitis patients, and in healthy controls.

229 wheeze," "Persistent eczema with later-onset rhinitis," "Persistent wheeze with later-onset rhinitis,

230 ose the term dual allergic rhinitis for this rhinitis phenotype.

231 LAR can coexist with other rhinitis phenotypes, especially AR.

232 the methods of allergen application and the rhinitis phenotypes.

233 ining 77.2% (n = 596) were classified as non-rhinitis/reference group.

234 ily symptom and medication scores and weekly rhinitis related quality of life scores during four poll

235 testing and clinically relevant symptoms of rhinitis related to their sensitization.

236 Gastroesophageal reflux/dysphagia and asthma/rhinitis represent a risk factor for the development of

237 P < .001; asthma, atopic dermatitis [AD] and rhinitis, respectively).

238 nts with severe persistent seasonal allergic rhinitis resulted in tissue eosinophilia and increases i

239 f any symptoms; and the incidence of wheeze, rhinitis, rhinoconjunctivitis, and eczema from birth to

240 Parent-reported symptoms of wheeze, rhinitis, rhinoconjunctivitis, or eczema from birth to 7

241 eze: RR: 1.10; 95% CI: 0.73, 1.65; P = 0.66; rhinitis: RR: 1.09; 95% CI: 0.81, 1.46; P = 0.59].

242 nel study of subjects with seasonal allergic rhinitis (SAR) and subjects without allergy and tested f

243 iscrepant group and in six seasonal allergic rhinitis (SAR), eight perennial local allergic rhinitis

244 with grass pollen allergy (seasonal allergic rhinitis [SAR] group, n = 16), sublingual immunotherapy

245 ed allergic patients (with seasonal allergic rhinitis [SAR]), and 12 nonatopic control subjects.

246 Total combined rhinitis score (TCRS), adverse events (AEs), adverse dru

247 sers without rhinitis and in those with mild rhinitis (scores 0-2).

248 xposure to PM(10) was associated with higher rhinitis severity (adjusted odds ratio [95% CI] for a 10

249 The score of rhinitis severity (range, 0-12), based on intensity of d

250 gan-specific symptoms, medication-free days, rhinitis severity and asthma control.

251 between long-term outdoor air pollution and rhinitis severity in adults.

252 median (1st quartile-3rd quartile) score of rhinitis severity was 4 (2-6).

253 at families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prev

254 ges in sIgE-defined and SPT-defined allergic rhinitis showed similar increasing trends.

255 Early transient rhinitis subjects were more likely of Indian ethnicity,

256 y was assessed by reductions in the allergic rhinitis symptom-medication score, and the asthma treatm

257 up displayed a 57% reduction in the allergic rhinitis symptom-medication score, which was markedly hi

258 Forty-eight patients with perennial rhinitis symptoms and positive SPT with seasonal allerge

259 ntinuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate.

260 Allergic rhinitis symptoms may commence as early as the first yea

261 Rhinitis symptoms were ascertained prospectively from bi

262 Occupational rhinitis tends to be higher in women, although is not cl

263 re we show in humans suffering from allergic rhinitis that merely reencountering the environmental co

264 The risk factors for asthma (e.g., allergic rhinitis) that were identified either by NLP or the abst

265 [OR], 0.69 [95% CI, 0.53-0.89] for allergic rhinitis), the sum of the n-3 PUFAs eicosapentaenoic aci

266 In patients with allergic rhinitis, the broader the IgE molecular sensitization pr

267 Allergic rhinitis to grass pollen (ARg) was defined as upper airw

268 This study aimed to identify different rhinitis trajectories in early childhood and their predi

269 Three rhinitis trajectory groups were identified: 7.6% (n = 59

270 initis," "Persistent wheeze with later-onset rhinitis," "Transient wheeze," "Eczema only" and "Rhinit

271 ing infancy increased the risk of asthma and rhinitis up to 16 years of age, particularly for nonalle

272 The MASK-rhinitis VAS is a reliable and valid tool to assess alle

273 Late transient rhinitis was associated with antenatal exposure to smoki

274 Persistent rhinitis was associated with male gender, paternal and m

275 Rhinitis was defined as one or more episodes of sneezing

276 Allergic rhinitis was defined as sensitisation and self-reported

277 Rhinitis was diagnosed by using a questionnaire focusing

278 in question used to assess the prevalence of rhinitis was from the ISAAC study.

279 Nonallergic rhinitis was least common (11.3%) and least severe.

280 Overall, rhinitis was present in 87%, and current asthma was pres

281 Rhinitis was present in 93.5%, and phenotypes identified

282 Allergic rhinitis was reported by 167 (20%) subjects.

283 Rhinitis was worse in patients with difficult-to-control

284 Childhood predictors for adult allergic rhinitis were atopic dermatitis, asthma and asymptomatic

285 Data on asthma, eczema, and allergic rhinitis were captured by validated International Study

286 Risks of allergic rhinitis were not associated with birth weight.

287 Patients with symptoms of rhinitis were recruited from a tertiary care outpatient

288 e association of tobacco smoke exposure with rhinitis, while the effect is mainly confined to non-all

289 und only for NO(2.) CONCLUSIONS: People with rhinitis who live in areas with higher levels of polluti

290 Next-generation care pathways for asthma and rhinitis will define the place of cat allergen avoidance

291 ic rhinitis (n = 12), or those with allergic rhinitis with asthma (n = 11).

292 ticipants with allergic rhinitis or allergic rhinitis with asthma had increased IFN-alpha2a, CCL3, an

293 rgen immunotherapy in patients with allergic rhinitis with or without asthma.

294 n 1 (odds ratio [OR], 3.3; 95% CI, 1.5-7.2), rhinitis with patterns 1 to 4 and 6 (OR, 2.2-4.3), and e

295 Perennial allergic rhinitis with seasonal exacerbations is the most severe

296 Perennial allergic rhinitis with seasonal exacerbations was most common (34

297 l permeability has been reported in allergic rhinitis, with histamine and type-2 inflammation being r

298 was associated with an increased severity of rhinitis, with similar adjusted odds ratios whatever the

299 are widely used to treat asthma and allergic rhinitis, with variable response rates.

300 nced a case of 34-year-old male with baker's rhinitis without asthma, and investigated responses of I